AD+sLATE– and AD−sLATE+ had lower tau burden and load, as measured by temporal and global Tau‐MaX, compared to AD+sLATE+, suggesting some degree of greater AD progression in the AD+sLATE+ group than in the AD+sLATE– group. Here, MAPT is linked to Alzheimer disease.